Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hair follicles, potentially offering fewer side effects.
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.